Drugs /

procarbazine

Back to Drugs List

Overview

Generic Name(s):
procarbazine
Trade Name(s):
Matulane, Natulan, Natunalar, and Natulanar
NCI Definition [1]:
A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.

Clinical Trials

View Clinical Trials for procarbazine

Procarbazine has been investigated in 4 clinical trials, of which 3 are open and 1 is closed. Of the trials investigating procarbazine, 1 is phase 1/phase 2 (1 open), 1 is phase 2 (0 open), and 2 are phase 3 (2 open).

IDH1 Mutation, IDH2 Mutation, and TNFRSF8 Expression are the most frequent biomarker inclusion criteria for procarbazine clinical trials.

Central nervous system lymphoma, classical hodgkin lymphoma, and diffuse large B-cell lymphoma are the most common diseases being investigated in procarbazine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Procarbazine
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Procarbazine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating procarbazine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
procarbazine [chemical/ingredient], Matulane, Natulan, Natulanar, Natunalar, n-isopropyl-p-(2-methylhydrazinomethyl)-benzamide, n-isopropyl-alpha-(2-methylhydrazino)-p-toluamide, n-4-isopropylcarbamoylbenzyl-n'-methylhydrazine, ibenzmethyzin, n-(1-methylethyl)-4-[(2-methylhydrazino)methyl]benzamide, n-methylhydrazine, 2-(p-isopropylcarbamoylbenzyl)-1-methylhydrazine, benzamide, n-(1-methylethyl)-4-((2-methylhydrazino)methyl)-, p-(2-methylhydrazinomethyl)-n-isopropylbenzamide, n-isopropyl-alpha-(2-methylhydrazino)-p-toluamide, procarbazine (product), procarbazin, n-4-isopropylcarbamoylbenzyl-n'-methylhydrazine, p-(n'-methylhydrazinomethyl)-n-isopropylbenzamide, procarbazine, procarbazina, n-(1-methylethyl)-4-((2-methylhydrazino)methyl)benzamide, procarbazinum, n-isopropyl-4-[(2-methylhydrazino)methyl]benzamide, 1-methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine, n-methylhydrazine, benzethyzin, procarbazine (substance), 4-((2-methylhydrazino)methyl)-n-isopropylbenzamide, procarbazine
Drug Categories [2]:
Alkylating agents
NCIT ID [1]:
C62072
SNOMED ID [1]:
C-781C0

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.